Welcome to our dedicated page for China Pharma SEC filings (Ticker: CPHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
China Pharma Holdings, Inc. files regulatory reports that document its specialty pharmaceutical operations in China, its NYSE American-listed common stock, and the activities of wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. Periodic and material-event filings cover operating and financial results, capital-structure disclosures, financing arrangements, and material agreements.
Recent 8-K disclosures include technology-transfer agreements involving invention patents for drug products and related research, registration, and technical services. Proxy and annual-meeting filings document board elections, shareholder votes, incentive-plan matters, reverse-split authorizations, and governance procedures, while Form 12b-25 notices address annual-report timing.
China Pharma Holdings reported Q1 2026 revenue of $0.98 million, down from $1.14 million a year earlier, as some key products faced weaker demand and competition from China’s centralized procurement system. The product mix shifted toward cardiovascular and cerebrovascular drugs, which became the largest revenue contributor.
The company posted a net loss of $1.14 million, wider than the $0.79 million loss in Q1 2025, mainly due to sharply higher amortization from recently acquired drug patents. Although gross margin improved to 29.0% from a prior gross loss, operating loss still reached $1.12 million.
Liquidity remains strained. Cash and cash equivalents were $0.17 million at March 31, 2026, and current liabilities exceeded current assets by $5.3 million. The CEO has advanced about $1.47 million in related-party loans, and management disclosed that these conditions create substantial doubt about the company’s ability to continue as a going concern.
During the quarter, China Pharma significantly expanded its intangible asset base by issuing 25,000,000 shares of common stock, valued at $15.0 million, to acquire two invention patents. This lifted total shares outstanding to 40,522,002 and increased stockholders’ equity but also materially diluted existing shareholders.
China Pharma Holdings, Inc. files its annual report for the year ended December 31, 2025, detailing a China-based generic and branded pharmaceutical business conducted through its wholly owned subsidiary Helpson. The company focuses on treatments for cardiovascular, central nervous system, infectious and digestive diseases, plus healthcare and protective products such as enzymes and masks.
China Pharma reports a negative gross margin of -3.2% in 2025, citing idle capacity, higher inventory impairment and lower product sales. Revenue is diversified across CNS, anti-infection, digestive and other categories, with anti-infection products the largest contributor. The filing emphasizes heavy exposure to PRC regulatory, pricing, medical insurance and procurement policies, as well as PCAOB inspection and HFCAA-related risks due to its U.S. listing.
China Pharma Holdings, Inc. submitted a Form 12b-25 notifying the SEC that its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 could not be filed on time and that the company intends to file the report no later than fifteen calendar days following the prescribed due date of March 31, 2026. Management provided preliminary estimates: revenue $4.1 million, cost of revenue ~$4.3 million, gross loss ~$0.1 million (gross loss margin ~3.2%), and net loss ~$3.19 million for 2025, and said fuller financial statements will appear in the Annual Report.
China Pharma Holdings, Inc. reported that its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd entered into a Technology Transfer Agreement on February 26, 2026 with Xiaoyan Zhang. The company will acquire an invention patent for Prinsepia Utilis Esterol sublingual tablets and related preparation methods.
As consideration, China Pharma agreed to pay $6.93 million in the form of its common stock at $0.55 per share, resulting in the planned issuance of 12,600,000 restricted shares of common stock. These shares will be issued to a non-U.S. person in an offshore transaction under Regulation S, and will not be registered under the U.S. Securities Act.
China Pharma Holdings, Inc. reported that its wholly owned subsidiary Hainan Helpson Medical & Biotechnology entered a Technology Transfer Agreement to acquire ownership of an invention patent for a Topiroxostat nanoemulsion and its preparation method from Xiaoyun Chen.
The transfer price is $8.82 million, to be paid in Company common stock at $0.70 per share, implying issuance of 12,600,000 restricted shares. Closing is expected by February 20, 2026. The shares will be issued in an offshore transaction to a non-U.S. person under Regulation S, without registration under the Securities Act.
China Pharma Holdings, Inc. reported results from its annual stockholders’ meeting for the fiscal year ended December 31, 2024. A total of 3,501,046 common shares, representing about 69.71% of outstanding shares as of the November 3, 2025 record date, were present in person or by proxy, providing a sufficient quorum.
Stockholders elected three independent directors—Gene Michael Bennett, Yingwen Zhang, and Baowen Dong—each receiving 3,500,416 to 3,500,418 votes for, with 628 to 630 votes withheld. Stockholders also approved an amendment to the Articles of Incorporation authorizing a reverse stock split at a ratio of up to 1-for-20 for the Company’s $0.001 par value common stock, with the Board retaining discretion over if and when to implement it. In addition, Amendment No. 3 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan was approved, with 3,500,258 votes for, 774 against, and 14 abstentions.
China Pharma Holdings, Inc. reports that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement with Juan Zhang to acquire an invention patent covering Ipragliflozin tablets and their preparation method. The agreed transfer price is $9.8 million, to be paid in the company’s common stock at $1.40 per share.
To satisfy this consideration, the company is to issue 7,000,000 restricted shares of common stock. These shares will be offered and issued to a non-U.S. person in an offshore transaction relying on Regulation S, meaning they will not be registered under the U.S. Securities Act or state securities laws.
China Pharma Holdings, Inc. reports that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, has entered into a Technology Transfer Agreement to acquire an invention patent for a Captopril microcapsule and its preparation method from an individual transferor. As consideration, the company values the transaction at $6.3 million, to be paid in shares of its common stock at $1.80 per share. In total, the company plans to issue 3,500,000 restricted common shares in connection with this technology transfer. The shares, if and when issued, will be offered in an offshore transaction to a non-U.S. person and will rely on Regulation S for exemption from registration under U.S. securities laws.
China Pharma Holdings (CPHI) called its Annual Meeting for December 30, 2025 to vote on three items: re‑elect three independent directors, authorize a reverse stock split of up to 1:20 at the Board’s discretion, and approve Amendment No. 3 to the Amended and Restated 2010 Long‑Term Incentive Plan to increase the share reserve by 500,000 shares (from 69,600 to 569,600).
The reverse split proposal is positioned as a tool to address potential NYSE American “low selling price” concerns; the Board notes prior reverse splits of 1‑for‑5 and 1‑for‑10 in 2024 and 2025. Fractional shares would be rounded up to a full share. Shares outstanding were 5,022,002 as of November 3, 2025, the record date. The proxy outlines standard voting mechanics, quorum (one‑third of outstanding), and recommends voting “FOR” all proposals. The filing also details 2024 audit fees of $125,000 and executive/director compensation, including CEO 2024 salary of $300,000 and outstanding restricted stock of 48,200 under the plan.
China Pharma Holdings (CPHI) reported Q3 2025 results showing continued losses amid tight liquidity. Revenue was $756,217, with a gross loss of $59,654 and net loss of $651,482 (loss per share $0.17). For the nine months, revenue was $2,918,271 and net loss was $1,965,421.
The company flagged substantial doubt about its ability to continue as a going concern. Cash and equivalents were $267,625 as of September 30, 2025, and current liabilities exceeded current assets by $4.3 million. Borrowings from the Chair/CEO totaled $1,413,340, supporting working capital.
Results improved year over year on lower depreciation and reduced inventory obsolescence, narrowing gross loss and operating loss. The company wrote off $13.7 million of long‑aged receivables in August 2025, sharply reducing the allowance. It also issued 1,760,000 shares for a patent asset valued at $2.446 million. A 1‑for‑10 reverse split took effect April 15, 2025; shares outstanding were 5,022,002 as of November 10, 2025.